Using 68Ga-JH04 PET/CT to image various cancers
68Ga-JH04 PET/CT in Patients With Various Types of Cancer
This study is testing a new imaging method using a special tracer to see if it can better detect and stage different types of cancer compared to current imaging techniques.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital of Fujian Medical University Academic / other |
| Locations | 1 site (Fuzhou, Fujian) |
| Trial ID | NCT06455735 on ClinicalTrials.gov |
What this trial studies
This study evaluates the diagnostic performance of a novel radiotracer, 68Ga-JH04, which targets fibroblast activation protein (FAP) in patients with different types of cancer. The research compares the imaging results of 68Ga-JH04 PET/CT with those of existing tracers like 68Ga-FAPI and 18F-FDG PET/CT. By focusing on carcinoma-associated fibroblasts, which are prevalent in over 90% of epithelial malignant tumors, this study aims to enhance tumor staging and restaging accuracy. Participants will undergo imaging to assess the effectiveness of this new approach in cancer diagnostics.
Who should consider this trial
Good fit: Ideal candidates include patients with various solid tumors who have confirmed histopathological findings.
Not a fit: Patients who are pregnant, lactating, or have severe hepatic and renal insufficiency may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic accuracy for various cancers, aiding in better treatment planning.
How similar studies have performed: Other studies have shown success with similar approaches targeting FAP, indicating potential for this novel tracer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Various solid tumors with available histopathological findings Signed informed consent Exclusion Criteria: pregnant or lactational women who suffered from severe hepatic and renal insufficiency
Where this trial is running
Fuzhou, Fujian
- The First Affiliated Hospital of Fujian Medical University — Fuzhou, Fujian, China (Recruiting)
Study contacts
- Principal investigator: Weibing Miao, MD — The First Affiliated Hospital, Fujian Medical University
- Study coordinator: Weibing Miao, MD
- Email: miaoweibing@126.com
- Phone: +86-0591-87981618
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.